Anthropic has opened a grants program offering up to $50,000 in free Claude access to researchers and early-stage biotech companies studying rare diseases, the company announced on July 20, 2026, as part of its broader AI for Science initiative.
Two tracks, one goal
The program splits into a basic-research track, pairing clinical researchers, patient advocacy groups and data scientists to study disease mechanisms, and a biotech track for early-stage companies trying to compress drug-development timelines. Anthropic said the credits, worth up to $50,000 over six months, can be used for tasks such as reviewing scientific literature, extracting insights from small or fragmented datasets, generating research hypotheses and standardizing disease terminology.
Applications close August 2, 2026, at 11:59 p.m. PST.
Why rare disease research lags
Rare diseases collectively affect an estimated 400 million people worldwide across more than 7,000 conditions, according to Anthropic, but small patient populations and thin datasets mean most receive little dedicated research funding or drug-development attention. The company argues that AI tools suited to synthesizing fragmented findings could shorten the path from an initial hypothesis to a testable treatment.
Anthropic named several partner organizations supporting the program, including the Monarch Initiative, which contributes disease-ontology and diagnostic resources; Every Cure, which works on repurposing existing drugs; the Centre for Population Genomics; and the Violet Research Institute, which focuses on ultra-rare genetic conditions.
Part of a broader science push
The grants extend Anthropic’s push into scientific and healthcare applications for Claude, following the company’s earlier launch of Claude Science, a dedicated research workbench.